Iovance Biotherapeutics, Inc. (IOVA)

Market Cap	2.19B
Revenue (ttm)	90.86M
Net Income (ttm)	-410.00M
Shares Out	304.78M
EPS (ttm)	-1.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,418,510
Open	7.24
Previous Close	7.37
Day's Range	7.05 - 7.34
52-Week Range	7.05 - 18.33
Beta	0.53
Analysts	Strong Buy
Price Target	23.33 (+224.93%)
Earnings Date	Feb 26, 2025

About IOVA

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combinat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 557
• Stock Exchange: NASDAQ
• Ticker Symbol: IOVA
• Website: https://www.iovance.com

Analyst Forecast

According to 9 analysts, the average rating for IOVA stock is "Strong Buy." The 12-month stock price forecast is $23.33, which is an increase of 224.93% from the latest price.

Price Target

$23.33

(224.93% upside)

Analyst Consensus: Strong Buy